ABSTRACT Twenty-four patients with reversible airflow obstruction under suboptimal control on conventional therapy entered a double-blind placebo-controlled trial of additional oral sustained release aminophylline. Assessment was by diary cards, twice daily PEFR, and weekly FEV,. Nineteen patients completed the trial satisfactorily. Eleven were improved subjectively by addition of aminophylline. The mean PEFR for all 19 patients rose from 232 1 min-' SEM-5, to 247 1 min-1 SEM±4 (p<00001); nine individuals showed a statistically significant improvement in mean PEFR and 10 showed an improvement of >200 ml in their FEV,. Improvement in PEFR on aminophylline was not at the expense of benefit from inhaled salbutamol. Unwanted effects of nausea, headache, and abdominal discomfort were recorded by 12 of the 24 patients entering the trial. Seventeen of the 19 patients completing the trial had plasma theophylline levels in the accepted therapeutic range of 10-20 mg 1-1. The drug doses required to achieve these levels varied from 8'6-30'8 mg kg-' 24 hr'1 in the patients with no clinical or biochemical evidence of liver disease. Oral aminophylline can improve control of airflow obstruction in patients with moderately severe disease who are already receiving multiple medication, but sideeffects often limit its use. The wide dose range required to achieve therapeutic plasma levels indicates that measurements of plasma theophylline are necessary for adequate interpretation of trials of theophylline compounds.
Intravenous theophylline preparations have been used in the management of asthma since 1937. Latterly, the increased availability of plasma theophylline measurements has led to a re-evaluation of intravenous dose schedules.1 2 It is generally agreed that peak plasma theophylline levels should be kept below 20 mg 1-1 while trough levels should remain above 10 mg 1-1. Similar principles apply to oral preparations.3 4 The recent development of a sustained release oral aminophylline preparation in a lipid base (Phyllocontin Continus Tablets, Napp Laboratories) has enabled the maintenance of such plasma theophylline levels when the drug is given 12-hourly. 3 We have examined whether this drug can improve the control of airflow obstruction in patients in whom existing treatment was providing suboptimal control.
Methods
Twenty-four patients, 13 men and 11 women, of mean age 57 years (range 19 to 71 years), with reversible airflow obstruction who attended Hammersmith Hospital regularly were entered into the trial (table 1) . Approval of the local ethics committee and informed consent from the patients were obtained. All patients had moderately severe airflow obstruction requiring multiple medication. Twenty were regularly using inhaled steroids and six of these required regular oral steroid therapy in addition. Twenty-three were receiving inhaled, and two oral, ,8-agonists; one used disodium cromoglycate and one ipratropium bromide. Individual dose requirements of aminophylline were determined during an open phase preceding the trial. Plasma theophylline was measured by high pressure liquid chromatography6 at times of peak (four to six hours post dosage) or trough (10 to 12 hours post dosage) plasma levels and were re-303 were measured on a dry spirometer. The best value of three estimates was recorded. Weekly blood samples were taken for analysis of plasma theophylline levels. This was performed by one of us (EB) on coded specimens, the trial code to be broken for ethical reasons if any plasma sample had a theophylline level of >25 mg l-1. The results of the plasma theophylline levels were withheld from the clinical assessor until after the end of the trial.
Results
The results from 19 patients were suitable for full analysis. Of the remaining five patients three (5, 17, and 18) withdrew because of side-effects and two were withdrawn because of irregular attendance (24) and irregular compliance with medication (7).
PLASMA THEOPHYLLINE LEVELS
Peak levels were between 15 and 20 mg 1-1 in nine patients, between 10 and 15 mg 1-1 in eight patients, and below the desired minimum of 10 mg 1-1 in two patients (table 1) . The daily maintenance dose used to achieve these levels varied between 70 and 30-8 mg kg-1, which represented doses from 450 to 2250 mg per 24 hours.
SUBJECTIVE AND OBJECTIVE BENEFITS
Eleven of the 19 patients recorded subjective benefit while on the active drug and none while on the placebo (table 2). The mean PEFR was slightly higher on the active drug (247 1 min-1, SEM+4) than on placebo (232 1 min-', SEM-+-5), (p<0 001) (figure). In nine patients PEFR on the active drug was significantly greater than on placebo, in nine there was no significant difference, and in one there was a small but statistically significant reduction in PEFR while on the active preparation ( Seven of the 19 patients failed to achieve either a statistically significant increase in daily PEFR or a mean increase of 200 ml or more in their FEV, while receiving the active preparation (table  2) . Of these, three (4, 13, and 16) were clearly unresponsive to the drug, since they achieved reasonable plasma levels of theophylline and were submaximally bronchodilated. Of the others, patient 10 was undoubtedly underdosed and patients 14 and 22 also might have benefited from larger loses. In addition patient 22 was already close to maximal bronchodilation. Patient 11 was one of two steroid unresponsive patients in the trial, and the mean increase in his FEV, of 180 ml represented a substantial part of his available reversibility.
We have data on the relation between the response to inhaled /3-agonists (salbutamol) and to oral aminophylline in eight of the patients (table  2) . Four responded to aminophylline and all retained their responsiveness to /3-agonists, so that the effects appeared to be additive. We did not attempt to show whether this additional benefit could have been achieved by increasing the dose of salbutamol. The four patients who did not respond to aminophylline nevertheless showed a good response to /-agonists. Our results suggest that a combination of oral aminophylline and salbutamol may be useful, particularly if side-effects from a higher dose of either drug used alone are proving troublesome.
A wide dose range (8-6 to 30-8 mg kg-1 24 hr-1) was required to achieve similar plasma levels in the 23 patients who had no overt liver disease or cardiac failure ( We were disappointed with the high incidence of nausea, headache, and abdominal discomfort found in patients receiving the active preparation. Twelve of the original 24 patients complained of such side-effects and in six they were sufficiently severe to exclude maintenance therapy with the drug. The side-effects tended to be most severe four to six hours after taking a dose and thus would coincide with the peak plasma levels.5 There was no relationship between the plasma theophylline levels at which side-effects occurred in different patients but in any individual patient the severity of the effects depended on the plasma theophylline concentration.
We conclude that sustained release oral aminophylline can produce modest but useful additional bronchodilatation in some patients whose airflow obstruction is inadequately controlled by other drugs. This may be particularly helpful if it is undesirable to increase the doses of existing medications such as oral steroids. Unfortunately, the high incidence of side-effects and the wide variation in optimum dosage for different patients restrict the drug's usefulness. However, our findings suggest that if asthmatic symptoms are inadequately controlled by inhaled fl-agonists then it may be more logical to add oral theophylline compounds rather than further (oral) 8-agonist therapy to their treatment. They also underline the need for estimating plasma theophylline levels in clinical trials of theophylline compounds. 
